New drug trial aims to halt liver damage from hepatitis b
NCT ID NCT07417553
Summary
This study is testing the safety of a new oral medication called Hydronidone in people with liver scarring caused by chronic hepatitis B. The main goal is to see how well the drug is tolerated and to check for side effects. All 150 participants will take the drug for 28 days while continuing their standard antiviral therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B-RELATED LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing Medical University Second Affiliated Hospital
Chongqing, Chongqing Municipality, 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.